Clinical Trial Update: RVU120 Rollover Study [Phase 2]

View source ↗

Summary

A Phase 2 rollover study of RVU120 in advanced solid tumors, acute myeloid leukemia, and high-risk myelodysplastic syndrome is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome
• Solid Tumors

Drugs mentioned

• RVU-120 (RVU120)

Snippet

Sponsor: Ryvu Therapeutics SA | Conditions: Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Status: NOT_YET_RECRUITING